Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20660178 | 0.94 | HPGD (0.55) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL16469685 | 0.92 | NR1H2 (0.47) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL1994758 | 0.92 | NR1H2 (0.47) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL30924502 | 0.92 | NR1H2 (0.47) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL2251826 | 0.90 | GPR119 (0.54) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL3044013 | 0.89 | GPR119 (0.55) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL7400409 | 0.88 | HPGD (0.54) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL103083 | 0.88 | HPGD (0.54) | HPGDKDM4EPKMGPR119RECQL | |
| SCHEMBL31565686 | 0.88 | GPR119 (0.56) | HPGDKDM4EPKMGPR119FAAH | |
| SCHEMBL31597046 | 0.88 | GPR119 (0.56) | HPGDKDM4EPKMGPR119FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 579 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115920036-A | Amphiphilic ROS-responsive photosensitizer-drug conjugate, ROS-responsive carrier-free nano-drug, preparation method and application | 西安交通大学 | 2023-04-07 | — | — | CN | claimed |
| CN-112047928-B | Isonicotinamide AChE-GSK3 double inhibitor and preparation method and application thereof | 中国药科大学 | 2022-09-23 | — | — | CN | claimed |
| CN-112047928-A | Isonicotinamide AChE-GSK3 double inhibitor and preparation method and application thereof | 中国药科大学 | 2020-12-08 | — | — | CN | claimed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| CN-122029157-A | Bilobalide derivatives for the treatment of neurological diseases and cancers | 香港中文大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688149-A1 | IRAK4 PROTACS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-5389631-A | A piperidinyl quinazoline or 1,3-benzodiazepine antiagglomerants of blood | MERCK & CO., INC. (US) | 1995-02-14 | — | — | US | disclosed |
| WO-1994026745-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0619814-A1 | OXADIAZOLE DERIVATIVES HAVING ACETYLCHOLINESTERASE-INHIBITORY AND MUSCARINIC AGONIST ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| WO-1994018981-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| US-5334596-A | Anticoagulants | MERCK & CO., INC. (US) | 1994-08-02 | — | — | US | disclosed |
| WO-1994012181-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-06-09 | — | — | WO | disclosed |
| WO-1994008577-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1993013083-A1 | OXADIAZOLE DERIVATIVES HAVING ACETYLCHOLINESTERASE-INHIBITORY AND MUSCARINIC AGONIST ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-08 | — | — | WO | disclosed |
| CN-1067883-A | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1993-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | HPGD 3881/4885KDM4E 4281/4885PKM 4802/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | HPGD 2278/4885KDM4E 125/4885PKM 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.